Early outcomes of lung resections in non-small cell lung cancer after COVID-19 pneumonia

Hekimoğlu, Barış; Beyoğlu, Muhammet Ali

doi:10.1016/j.asjsur.2022.04.080

Cited by 3 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, it is recommended that patients should wait for a minimum of four weeks before undergoing elective thoracic surgery after a history of asymptomatic COVID-19. [6] Hekimoglu and Beyoglu [7] found that the mean duration of COVID-19 infection to lung resection was 25.79±15 weeks and it was 27.8±22 weeks in a previous study. [7] The results of this study showed that the period between infection and surgery did not affect postoperative complications.…”

Section: Discussionmentioning

confidence: 84%

“…[6] Hekimoglu and Beyoglu [7] found that the mean duration of COVID-19 infection to lung resection was 25.79±15 weeks and it was 27.8±22 weeks in a previous study. [7] The results of this study showed that the period between infection and surgery did not affect postoperative complications. This result may be related to the fact that the mean time was always more than four weeks, which is the recommended time interval.…”

Section: Discussionmentioning

confidence: 84%

“…This result is similar to the result of another study, which found a mean time to chest tube removal of 6.36±2.46 days. [7] The main limitations to this study are its single-center, retrospective design. As the comparison between post-COVID-19 and other thoracotomy patients is beyond the scope of our study, further studies are needed.…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Assessment of complications and surgical timing in post-COVID-19 thoracotomy patients: A single-center experience

Yıldırım Güçlü,

Mustafa Yenigün,

Kocaman

et al. 2023

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Background: This study aims to assess the complications in post-novel coronavirus disease 2019 (COVID-19) thoracotomy patients and to evaluate the time interval between infection and surgery and the effect of vaccine timing and vaccine type in these patients. Methods: Between May 2020 and January 2022, a total of 74 patients (34 males, 40 females; mean age: 54.5±13.7 years; range, 22 to 27 years) who had COVID-19 infection and underwent thoracic surgery were retrospectively analyzed. Data including demographic and clinical characteristics, the surgery type, length of intensive care unit and hospital stay, and postoperative complications were recorded. Complications were defined as respiratory, cardiac, thrombotic, and other complications. The time period between COVID-19 infection and surgery was noted. All patients were questioned regarding their vaccination status. Results: Having a symptomatic COVID-19 infection did not significantly affect the development of postoperative complications and length of intensive care unit or hospital stay. Thoracic involvement was the main factor which affected the length of intensive care unit and hospital stay during COVID-19 infection (p=0.004 and p=0.003, respectively). Conclusion: Our study results suggest that the length of hospital and intensive care unit stay is related to the time period between infection and surgery. The longer that the patient waits after COVID-19 infection, the less time that the patient stays in the hospital.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Assessment of complications and surgical timing in post-COVID-19 thoracotomy patients: A single-center experience

Yıldırım Güçlü,

Mustafa Yenigün,

Kocaman

et al. 2023

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

show abstract

“…This observation might explain the absence of serious postoperative complications in the PREOP-COV group and account for the lack of difference between groups in terms of their early postoperative outcomes. The study of Hekimoglu and Bemoglu reported that anatomic pneumonectomy may be safely performed without increasing early postoperative morbidity and mortality in NSCLC patients with a history of COVID-19 pneumonia [25] .…”

Section: Commentmentioning

confidence: 99%

Early radical lung cancer outcome after prompt recovery from COVID-19 infection: A real-world study

Ma,

Ge,

Feng

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There has been an increase in the number of patients with lung cancer who had previously contracted SARS-CoV-2 and currently require surgery. This study was to share the early postoperative outcomes in patients who underwent radical lung cancer surgery after early recovery of COVID-19 infection. Methods We retrospectively collected data for 99 patients who had undergone lung cancer surgery in our hospital during January 2022 and January 2023 (including the peak of the COVID-19 crisis）. The patients were divided into two groups according to the inclusion criteria and exclusion criteria. One of these included individuals with a history of SARS-CoV-2 infection. Perioperative and follow-up data at 30-day and 90-day were recorded. Results There were no statistical differences between groups (p > 0.05) in terms of their postoperative complications or 30-day and 90-day postoperative readmission rates. However, there were significant differences between groups (p < 0.05) in terms of their tumor sizes, pathological stages, total drainage volumes, drainage diversion times, and hospital stays. Conclusions The results of the present trial suggested that it is safe to implement radical curative lung cancer surgery in patients without pulmonary impairment and in the early stages (2–4 weeks) of recovery from SARS-CoV-2 infection.

show abstract

Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis

Wu,

Liu,

Wang

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Lung cancer patients with coronavirus disease 2019 (COVID-19) infection experience high mortality rates. The study aims to determine the risk factors for mortality in lung cancer patients with COVID-19 infection. Materials and methods Followed the PRISMA reporting guidelines, PubMed, Embase, and Web of Science were systematically searched to February 20, 2023, for studies of lung cancer patients with COVID-19 infection. The main outcome of interest was the risk factor for mortality. We also compared the mortality rate of those patients among different continents. A pooled risk ratio (RR) with 95% CI was presented as the result of this meta-analysis. Results Meta-analysis of 33 studies involving 5018 patients showed that pooled mortality rate of lung cancer in COVID-19 patients was 0.31 (95% CI: 0.25–0.36). Subgroup analysis based on the continents showed significant difference of the mortality rate was observed between Asia and the rest of world (χ2 = 98.96, P < 0.01). Older age (SMD: 0.24, 95% CI: 0.09–0.40, P < 0.01), advanced lung cancer (RR: 1.14, 95% CI: 1.04–1.26, P < 0.01), coexisting comorbidities such as hypertension (RR: 1.17, 95% CI: 1.01–1.35, P = 0.04) and cardiovascular disease (RR: 1.40, 95% CI: 1.03–1.91, P = 0.03) were associated with higher risk of mortality rate in those patients. Conclusions Findings of this meta-analysis confirms an increased risk of mortality in lung cancer patients with COVID-19 infection, whose risk factors for these patients appear to be exacerbated by older age, advanced-stage lung cancer, and comorbidities such as hypertension and cardiovascular disease.

show abstract

Early outcomes of lung resections in non-small cell lung cancer after COVID-19 pneumonia

Cited by 3 publications

References 19 publications

Assessment of complications and surgical timing in post-COVID-19 thoracotomy patients: A single-center experience

Assessment of complications and surgical timing in post-COVID-19 thoracotomy patients: A single-center experience

Early radical lung cancer outcome after prompt recovery from COVID-19 infection: A real-world study

Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis

Contact Info

Product

Resources

About